Murphy & Mullick Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Murphy & Mullick Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$250K	Buy	3,989 +32	+0.8%	+$2.02K	0.15%	117
2026 Q2	$228K	Buy	3,957 +3	+0.1%	+$172	0.14%	129
2026 Q1	$240K	Buy	3,954 +646	+20%	+$37.7K	0.18%	118
2025 Q4	$178K	Sell	3,308 -762	-19%	-$36.7K	0.13%	151
2025 Q3	$184K	Sell	4,070 -865	-18%	-$40.4K	0.14%	147
2025 Q2	$215K	Sell	4,935 -503	-9%	-$24.7K	0.17%	122
2025 Q1	$332K	Buy	5,438 +2	+0%	+$117	0.32%	74
2024 Q4	$307K	Buy	+5,436	New	+$304K	0.28%	84

Other funds holding BMY

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Murphy & Mullick Capital Management's BMY Position: Q3 2026 in Review

Murphy & Mullick Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.81% in Q3 2026, buying an estimated $2.02K and bringing the position to 3,989 shares worth $250K. The position accounts for 0.15% of the portfolio, ranked #117.

Murphy & Mullick Capital Management first reported a position in BMY in Q4 2024 and has held it in 8 quarters since. The position peaked at $332K in Q1 2025. 1,758 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

Murphy & Mullick Capital Management held 3,989 shares of Bristol-Myers Squibb worth $250K as of Q3 2026.
Murphy & Mullick Capital Management bought 32 Bristol-Myers Squibb shares in Q3 2026, an estimated $2.02K.
Bristol-Myers Squibb made up 0.15% of Murphy & Mullick Capital Management's portfolio in Q3 2026, its #117 holding.
Murphy & Mullick Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 8 quarters since.
Murphy & Mullick Capital Management's Bristol-Myers Squibb position peaked at $332K in Q1 2025.
1,758 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.